Financial Gravity Asset Management Inc. lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 146.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 5,225 shares of the biotechnology company's stock after buying an additional 3,101 shares during the period. Financial Gravity Asset Management Inc.'s holdings in United Therapeutics were worth $2,339,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Fifth Third Bancorp raised its holdings in United Therapeutics by 2.2% in the 2nd quarter. Fifth Third Bancorp now owns 2,426 shares of the biotechnology company's stock valued at $572,000 after acquiring an additional 53 shares during the period. Hancock Whitney Corp raised its holdings in United Therapeutics by 0.4% in the 3rd quarter. Hancock Whitney Corp now owns 12,183 shares of the biotechnology company's stock valued at $2,550,000 after acquiring an additional 53 shares during the period. Arizona State Retirement System raised its holdings in United Therapeutics by 0.5% in the 2nd quarter. Arizona State Retirement System now owns 12,231 shares of the biotechnology company's stock valued at $2,882,000 after acquiring an additional 57 shares during the period. Victory Capital Management Inc. raised its holdings in United Therapeutics by 0.4% in the 2nd quarter. Victory Capital Management Inc. now owns 15,932 shares of the biotechnology company's stock valued at $3,754,000 after acquiring an additional 58 shares during the period. Finally, Federated Hermes Inc. raised its holdings in United Therapeutics by 0.5% in the 1st quarter. Federated Hermes Inc. now owns 13,603 shares of the biotechnology company's stock valued at $2,441,000 after acquiring an additional 61 shares during the period. 95.63% of the stock is currently owned by institutional investors and hedge funds.
Get United Therapeutics alerts:Insider Activity
In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $258.95, for a total transaction of $1,553,700.00. Following the completion of the transaction, the executive vice president now owns 36,397 shares of the company's stock, valued at $9,425,003.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $258.95, for a total transaction of $1,553,700.00. Following the completion of the transaction, the executive vice president now owns 36,397 shares of the company's stock, valued at $9,425,003.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Judy D. Olian sold 1,010 shares of United Therapeutics stock in a transaction on Friday, December 9th. The stock was sold at an average price of $282.00, for a total transaction of $284,820.00. Following the transaction, the director now directly owns 7,655 shares of the company's stock, valued at approximately $2,158,710. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 207,390 shares of company stock valued at $54,841,715. Insiders own 12.40% of the company's stock.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $261.70 on Friday. United Therapeutics Co. has a fifty-two week low of $158.38 and a fifty-two week high of $283.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The firm has a market capitalization of $11.93 billion, a P/E ratio of 17.80, a P/E/G ratio of 1.55 and a beta of 0.62. The company's 50 day moving average price is $270.84 and its two-hundred day moving average price is $241.25.United Therapeutics (NASDAQ:UTHR – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.57 by $1.34. The firm had revenue of $516.00 million during the quarter, compared to the consensus estimate of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. On average, equities analysts forecast that United Therapeutics Co. will post 16.57 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. UBS Group assumed coverage on shares of United Therapeutics in a report on Tuesday, December 6th. They issued a "buy" rating and a $320.00 price target on the stock. Wedbush raised their target price on shares of United Therapeutics from $250.00 to $305.00 in a report on Thursday, November 3rd. HC Wainwright raised their target price on shares of United Therapeutics from $255.00 to $300.00 and gave the stock a "buy" rating in a report on Thursday, November 3rd. Oppenheimer raised their target price on shares of United Therapeutics from $325.00 to $375.00 and gave the stock an "outperform" rating in a report on Thursday, November 3rd. Finally, The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a research report on Monday, December 5th. They set a "sell" rating and a $230.00 price target on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $283.64.
United Therapeutics Company Profile
(Get Rating)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.